Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Just because the system involves humans, it does not make it human
August 14, 2025 - - Latest News -
Australian company Mirugen secures backing to process cell technology
August 13, 2025 - - Latest News -
AccessCR’s awards celebrate partnerships between lived experience and science
August 13, 2025 - - Latest News -
Firebrick says Nasodine COVID-19 patent accepted in Europe
August 13, 2025 - - Australian Biotech -
Orthocell advances US rollout of nerve repair product Remplir
August 13, 2025 - - Australian Biotech -
AVITA Medical successfully completes Australian equity raise
August 13, 2025 - - Australian Biotech -
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech